全球经动脉化疗栓塞市场

预计到 2030 年，全球经动脉化疗栓塞术市场规模将达到 218 亿美元

全球经动脉化疗栓塞术市场规模预计在2024年为168亿美元，预计到2030年将达到218亿美元，在分析期内（2024-2030年）的复合年增长率为4.5%。化疗是本报告分析的细分市场之一，预计其复合年增长率为4.3%，到分析期结束时规模将达到115亿美元。放射治疗药物细分市场在分析期间的复合年增长率预计为5.1%。

美国市场规模估计为 46 亿美元，中国市场预期复合年增长率为 8.1%

美国经动脉化疗栓塞术市场规模预计2024年达到46亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到45亿美元，在2024-2030年的分析期间内，复合年增长率为8.1%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个国家的复合年增长率分别为1.9%和3.5%。在欧洲，预计德国的复合年增长率为2.6%。

全球「经动脉化疗栓塞术」市场—主要趋势与驱动因素摘要

为什么经动脉化疗栓塞术会成为肝癌治疗的全球标准？

经肝动脉化疗栓塞术 (TACE) 正在成为原发性肝细胞癌 (HCC)（最常见的原发性肝癌）的首选和标准治疗方法。与全身化疗不同，TACE 将高剂量的化疗直接输送到为肿瘤供血的肝动脉，同时切断血液供应，导致药物标靶暴露和局部肿瘤坏死。这种双重机制已被证明对合格进行手术切除或肝臟移植的患者特别有效。 TACE 也被用作等待移植患者的过渡疗法，有助于稳定病情进展。在全球范围内，由于慢性乙型和丙型肝炎感染、非酒精性脂肪肝病 (NAFLD) 和酒精性肝损伤等因素，肝癌的发生率正在上升。这些趋势导致对 TACE 等局部疗法的需求增加，这些疗法可以提高存活率和疾病控制率，同时降低全身毒性。国际肿瘤学会的新指南建议将 TACE 作为肝臟恶性肿瘤的第一线或联合治疗，强化其在治疗途径中的核心作用，并增加其在全球医疗保健提供者中的采用率。

药物输送和影像技术的创新如何改善 TACE 效果？

栓塞材料、导管技术和影像导引系统的进步显着提高了TACE的疗效。药物释放型微球（DEB）能够在肿瘤部位控制并持续释放化疗药物，取代了许多市场上传统的碘油製剂，降低了全身暴露量并提高了缓解率。微导管和可控输送系统的技术进步使得复杂血管解剖结构的精准导航成为可能，最大限度地减少了对健康肝组织的伤害。同时，锥状射束CT和3D血管摄影检查等即时影像技术彻底改变了治疗过程中的可视化，实现了高度精准的给药并可立即确认治疗成功。这些技术创新也为个人化治疗计画铺平了道路，在製定栓塞类型、颗粒大小和给药方案时，肿瘤大小、位置和血管系统均被纳入考虑。此外，人工智慧与影像分析的整合正开始协助介入放射科医师进行治疗前规划和治疗后结果评估，从而提高一致性和长期预后。这些技术主导的改进不仅改善了临床结果，而且扩大了 TACE 的候选人库。

全球医疗保健领域是否已准备好广泛使用 TACE？

全球医疗生态系统对经动脉化疗栓塞术的广泛应用日益开放，这得益于介入放射学基础设施的不断扩展和训练有素的专家数量的不断增加。在高所得国家，先进的影像实验室、多学科肿瘤委员会和专门的肿瘤学途径使得TACE能够无缝整合到肝癌治疗方案中。同时，中等收入国家意识到TACE在资源匮乏、难以获得先进手术和全身治疗的环境中的价值，正在大力投资微创癌症治疗。在肝癌发病率特别高的亚太地区，各国政府正在将TACE纳入公共医疗保险计划和国家癌症控制计划，刺激了市场的快速扩张。私部门对门诊手术中心和肿瘤医院的投资也促进了TACE在都市区和郊区的普及。然而，低收入国家仍面临挑战，影像学能力不足，缺乏熟练的介入放射科医师。国际卫生组织透过移动 IR 单位、培训计划和官民合作关係关係来改善治疗可及性的努力正在开始解决这些差异，并正在逐步实现这种延长生命的治疗的民主化。

经动脉化疗栓塞市场的成长受到多种因素的推动…

经动脉化疗栓塞术市场的成长受到多种因素的驱动，这些因素源自于疾病流行、医疗创新和不断发展的医疗保健系统。主要驱动因素是人口老化、病毒性肝炎、饮酒和代谢紊乱导致的全球肝癌负担不断增加。随着患者数量的增加，对TACE等中间疗法的需求也随之增长，这些疗法弥补了治癒性治疗和安宁疗护之间的治疗差距。从技术角度来看，下一代栓塞剂、改进的导管导航工具以及人工智慧影像分析的发展提高了该手术的有效性和安全性。医疗保健提供者正在接受TACE，因为与全身化疗和手术相比，TACE侵入性更小、恢復时间更短、併发症发生率更低。此外，门诊介入性肿瘤治疗日益受到偏好，也扩大了医院和专科诊所对TACE的需求。保险报销的简化，尤其是在已开发经济体和快速发展经济体，提高了患者获得治疗的管道，因为TACE现已可作为第一线治疗。设备製造商、製药公司和介入放射学网路之间的策略合作也推动创新和市场渗透。这些因素共同作用，使TACE成为全球肝癌多学科治疗的重要支柱。

部分

产品类型（化疗药物、放疗药物、药物释放型颗粒）、适应症（不可切除的HCC、早期HCC）、最终用户（医院、诊所、癌症研究中心、其他最终用户）

受访公司范例（总合42家公司）

• Advaxis Inc.
• Bayer AG
• Bellicum Pharmaceuticals
• Boston Scientific Corporation
• CELGENE Corporation
• Cook Medical
• F. Hoffmann-La Roche Ltd
• Hikma Pharmaceuticals PLC
• Isofol Medical AB
• Kaneka Corporation
• Medtronic plc
• Merck & Co., Inc.
• Merit Medical Systems, Inc.
• Nippon Kayaku Co., Ltd.
• Novartis AG
• Pfizer Inc.
• Siemens Healthineers AG
• Sirtex Medical Limited
• Spectrum Pharmaceuticals, Inc.
• Terumo Corporation

关税影响係数

全球产业分析师根据公司总部所在国家、製造地、进出口（成品和原始OEM）来预测其竞争地位的变化。这种复杂且多面向的市场动态预计将以多种方式影响竞争对手，包括人为提高销货成本、盈利下降、供应链重组以及其他微观和宏观市场动态。

全球产业分析师密切关注来自全球顶尖首席经济学家（14,949位）、智库（62家）以及贸易和产业协会（171家）的专家的意见，以评估其对生态系统的影响并应对新的市场现实。我们追踪了来自每个主要国家的专家和经济学家对关税及其对本国影响的看法。

全球产业分析师预计，这场动盪将在未来2-3个月内逐渐平息，新的世界秩序将更加清晰地建立。全球产业分析师正在即时追踪这些事态发展。

2025年4月：谈判阶段

在4月的报告中，我们将探讨关税对全球整体市场的影响，并提供区域市场调整。我们的预测是基于历史数据和不断变化的市场影响因素。

2025年7月：最终关税调整

在各国宣布最终重置后，客户将在 7 月收到免费更新，最终更新将包含明确的关税影响分析。

相互和双边贸易及关税影响分析：

美国<>中国<>墨西哥<>加拿大<>欧盟<>日本<>印度<>其他176个国家

领先的产业经济学家：全球产业分析师知识库追踪了 14,949 位经济学家，其中包括来自民族国家、智库、贸易和产业协会、大型企业以及各领域专家的最具影响力的首席经济学家，他们共用了这场前所未有的全球经济状况模式转移的影响。我们超过 16,491 份报告大多遵循基于里程碑的两阶段发布计划。

目录

第一章调查方法

第二章执行摘要

• 市场概览
• 主要企业
• 市场趋势和驱动因素
• 全球市场展望

第三章市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 西班牙
• 俄罗斯
• 其他欧洲国家
• 亚太地区
• 澳洲
• 印度
• 韩国
• 其他亚太地区
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中东
• 伊朗
• 以色列
• 沙乌地阿拉伯
• 阿拉伯聯合大公国
• 其他中东地区
• 非洲

第四章 竞赛

Global Transarterial Chemoembolization Market to Reach US$21.8 Billion by 2030

The global market for Transarterial Chemoembolization estimated at US$16.8 Billion in the year 2024, is expected to reach US$21.8 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Chemotherapeutic Agents, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$11.5 Billion by the end of the analysis period. Growth in the Radio Therapeutic Agents segment is estimated at 5.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.6 Billion While China is Forecast to Grow at 8.1% CAGR

The Transarterial Chemoembolization market in the U.S. is estimated at US$4.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.5 Billion by the year 2030 trailing a CAGR of 8.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 3.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.

Global "Transarterial Chemoembolization" Market - Key Trends & Drivers Summarized

Why Is Transarterial Chemoembolization Becoming a Standard for Liver Cancer Treatment Worldwide?

Transarterial chemoembolization (TACE) has emerged as a preferred and increasingly standardized therapy for intermediate-stage hepatocellular carcinoma (HCC), the most common form of primary liver cancer. Unlike systemic chemotherapy, TACE delivers high-dose chemotherapy directly into the hepatic artery feeding the tumor while simultaneously blocking the blood supply, leading to targeted drug exposure and localized tumor necrosis. This dual mechanism has proven particularly effective in patients ineligible for surgical resection or liver transplantation. TACE is also being adopted as a bridging therapy for patients awaiting transplantation, helping to stabilize disease progression. Globally, the incidence of liver cancer is rising due to factors such as chronic hepatitis B and C infections, non-alcoholic fatty liver disease (NAFLD), and alcohol-related liver damage. These trends have increased demand for locoregional therapies like TACE, which offer improved survival rates and disease control with a lower systemic toxicity profile. Emerging guidelines by international oncology societies are endorsing TACE as a frontline or combination treatment for liver malignancies, thereby reinforcing its central role in therapeutic pathways and boosting adoption among healthcare providers worldwide.

How Are Drug Delivery Innovations and Imaging Technologies Enhancing TACE Outcomes?

The effectiveness of TACE has significantly improved through advancements in embolic materials, catheter technology, and imaging guidance systems. Drug-eluting beads (DEBs), which allow for controlled and sustained release of chemotherapy agents at the tumor site, have largely replaced traditional lipiodol-based formulations in many markets, reducing systemic exposure and improving response rates. Technological enhancements in microcatheters and steerable delivery systems have made it possible to navigate complex vascular anatomies with precision, minimizing damage to healthy liver tissue. At the same time, real-time imaging modalities such as cone-beam CT and 3D angiography have revolutionized intra-procedural visualization, allowing for highly targeted delivery and immediate verification of treatment success. These innovations have also paved the way for personalized treatment plans, where tumor size, location, and vascularity are factored into decisions on embolic type, particle size, and dosing schedules. Additionally, the integration of AI in imaging analytics is beginning to assist interventional radiologists in pre-procedural planning and post-procedural outcome assessments, improving consistency and long-term prognoses. These technology-led improvements are not only boosting clinical outcomes but also expanding the candidate pool for TACE.

Is the Global Healthcare Landscape Ready for the Widespread Adoption of TACE?

The global healthcare ecosystem is increasingly receptive to the widespread adoption of transarterial chemoembolization, supported by expanding interventional radiology infrastructure and a growing base of trained specialists. In high-income countries, the presence of sophisticated imaging suites, multidisciplinary tumor boards, and dedicated oncology pathways has allowed for the seamless integration of TACE into liver cancer care algorithms. Meanwhile, middle-income countries are investing heavily in minimally invasive cancer care, recognizing TACE’s value in resource-constrained settings where access to advanced surgery or systemic therapies is limited. In Asia-Pacific, where liver cancer incidence is particularly high, governments are including TACE in public insurance schemes and national cancer control programs, fueling rapid market expansion. Private sector investments in ambulatory surgical centers and oncology-focused hospitals are also contributing to the increased availability of TACE in urban and peri-urban regions. However, challenges remain in low-income countries due to inadequate imaging capabilities and a shortage of skilled interventional radiologists. Efforts by global health organizations to improve access through mobile IR units, training programs, and public-private partnerships are beginning to address these disparities, gradually democratizing access to this life-extending procedure.

The Growth in the Transarterial Chemoembolization Market Is Driven by Several Factors…

The growth in the transarterial chemoembolization market is driven by several factors rooted in disease prevalence, medical innovation, and healthcare system evolution. A primary driver is the rising global burden of liver cancer, fueled by aging populations, viral hepatitis, alcohol consumption, and metabolic disorders. As patient volumes increase, so does the need for intermediate therapies like TACE that fill the treatment gap between curative and palliative care. From a technological perspective, the development of next-generation embolic agents, improved catheter navigation tools, and AI-powered imaging analytics is enhancing procedural efficacy and safety. Healthcare providers are embracing TACE for its minimally invasive profile, shorter recovery times, and lower complication rates compared to systemic chemotherapy or surgery. Additionally, the growing preference for outpatient interventional oncology treatments is expanding demand for TACE in both hospital and specialty clinic settings. Insurance reimbursements, particularly in developed and rapidly developing economies, are being streamlined to cover TACE as a first-line therapy, increasing patient access. Strategic collaborations between device manufacturers, pharma companies, and interventional radiology networks are also fostering innovation and market penetration. Collectively, these factors are positioning TACE as a vital pillar in the multidisciplinary management of liver cancer worldwide.

SCOPE OF STUDY:

The report analyzes the Transarterial Chemoembolization market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Chemotherapeutic Agents, Radio Therapeutic Agents, Drug-Eluting Particles); Indication (Unresectable HCC, Early-Stage HCC); End-Use (Hospitals, Clinics, Cancer Research Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Advaxis Inc.
• Bayer AG
• Bellicum Pharmaceuticals
• Boston Scientific Corporation
• CELGENE Corporation
• Cook Medical
• F. Hoffmann-La Roche Ltd
• Hikma Pharmaceuticals PLC
• Isofol Medical AB
• Kaneka Corporation
• Medtronic plc
• Merck & Co., Inc.
• Merit Medical Systems, Inc.
• Nippon Kayaku Co., Ltd.
• Novartis AG
• Pfizer Inc.
• Siemens Healthineers AG
• Sirtex Medical Limited
• Spectrum Pharmaceuticals, Inc.
• Terumo Corporation

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Transarterial Chemoembolization - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Liver Cancer and Hepatocellular Carcinoma Propels Demand for TACE Procedures
  • Increasing Preference for Minimally Invasive Oncology Treatments Expands TACE Adoption
  • Advancements in Drug-Eluting Beads Technology Strengthen Clinical Outcomes and Market Appeal
  • Expanding Use of TACE in Palliative Cancer Care Throws the Spotlight on Targeted Therapies
  • Growing Acceptance of TACE as a First-Line Treatment Drives Procedural Volumes Globally
  • Integration of Imaging Guidance Systems Enhances Precision and Spurs Market Innovation
  • Favorable Reimbursement Scenarios in Developed Markets Support Wider Procedural Uptake
  • Aging Population and Comorbidities Increase Patient Pool for Non-Surgical Therapies
  • Expansion of Interventional Radiology Infrastructure in Emerging Markets Sustains Global Growth
  • Improved Catheterization Techniques Propel Success Rates and Professional Confidence in TACE
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Transarterial Chemoembolization Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Transarterial Chemoembolization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Transarterial Chemoembolization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Chemotherapeutic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Chemotherapeutic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Chemotherapeutic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Radio Therapeutic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Radio Therapeutic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Radio Therapeutic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Drug-Eluting Particles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Drug-Eluting Particles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Drug-Eluting Particles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Unresectable HCC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Unresectable HCC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Unresectable HCC by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Early-Stage HCC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Early-Stage HCC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Early-Stage HCC by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Cancer Research Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Cancer Research Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Cancer Research Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 32: USA Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• JAPAN
  • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• CHINA
  • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 59: China Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: China 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• EUROPE
  • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Transarterial Chemoembolization by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for Transarterial Chemoembolization by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• FRANCE
  • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 80: France Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: France 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• GERMANY
  • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Germany 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Italy 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 107: UK Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: UK 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Spain 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Russia 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Transarterial Chemoembolization by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 15-Year Perspective for Transarterial Chemoembolization by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Australia 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• INDIA
  • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 164: India Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: India 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 167: India Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: South Korea 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Transarterial Chemoembolization by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Latin America 15-Year Perspective for Transarterial Chemoembolization by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Argentina 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Brazil 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Mexico 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Transarterial Chemoembolization by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Middle East 15-Year Perspective for Transarterial Chemoembolization by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Iran 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Israel 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: UAE 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• AFRICA
  • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Africa 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION